Study guide
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration
Key Takeaways Explain This Topic AI
Oncology Nurse Navigators (ONNs) apply core competencies established by the Oncology Nursing Society (ONS) and the Academy of Oncology Nurse & Patient Navigators (AONN+) to eliminate structural, financial, transportation, and clinical barriers across the cancer continuum.
Racial and socioeconomic disparities in breast cancer remain substantial: while White women have a slightly higher overall incidence, Black women have a 40% higher mortality rate, higher incidence of aggressive triple-negative breast cancer (TNBC), and greater delays from abnormal screening to diagnostic biopsy and treatment initiation.
Financial toxicity represents an adverse effect of cancer care characterized by substantial out-of-pocket expenses, debt, and employment disruption; oncology nurses mitigate this through proactive distress screening, co-pay assistance navigation, and social work collaboration.
Navigation removes specific barriers, including transportation, language, health literacy, work schedules, and cost, to shorten the time from abnormal screening to diagnosis and treatment.
At multidisciplinary tumor boards, the nurse contributes functional status, comorbidities, support systems, and patient preferences, then translates recommendations back to the patient.
Last updated: September 2026
Professional Oncology Nurse Navigation: Origins and Core Competencies
Patient navigation in oncology originated in 1990 through the visionary work of surgical oncologist Dr. Harold P. Freeman at Harlem Hospital in New York City. Dr. Freeman documented that poor, predominantly Black women diagnosed with breast cancer in Harlem often presented late (about half with stage III or IV disease) and had a 5-year survival of about 39%. Free screening plus navigation to remove financial, logistical, and systemic barriers shifted diagnoses to earlier stages and raised 5-year survival to about 70%.
Today, Oncology Nurse Navigation is an established specialty nursing practice defined by standardized core competencies published by the Oncology Nursing Society (ONS) and the Academy of Oncology Nurse & Patient Navigators (AONN+) . Oncology Nurse Navigators (ONNs) are clinically experienced registered nurses who utilize specialized breast oncology knowledge to guide patients, families, and caregivers across the entire cancer care continuum—from abnormal imaging screening, through tissue biopsy, multidisciplinary staging, acute surgical and adjuvant therapies, into survivorship or end-of-life care.
The Four Core Competency Domains of Oncology Nurse Navigation
Care Coordination and Continuum Management : ONNs serve as the central clinical point of contact, coordinating complex clinical appointments across surgical oncology, medical oncology, radiation oncology, diagnostic radiology, plastic surgery, and genetics. They track clinical milestones to minimize diagnostic and treatment delays, ensuring care transitions occur without procedural friction.
Education, Communication, and Health Literacy : ONNs assess patient health literacy, cognitive baseline, and emotional readiness. They translate complex histopathologic terminology, genomic recurrence assay scores, surgical options, and systemic therapy regimens into accessible, patient-centered language, empowering informed decision-making.
Individualized Barrier Assessment and Advocacy : ONNs systematically identify logistical, financial, cultural, and psychosocial barriers to care. Navigators facilitate transportation assistance, coordinate interpreter services for patients with limited English proficiency, arrange lodging for rural patients, and address childcare or eldercare constraints.
Professional Practice and Quality Improvement : ONNs participate in multidisciplinary tumor boards, lead clinical quality audits, track clinical navigation metrics (such as time from abnormal screening mammogram to core needle biopsy, and time from biopsy to first oncology consult), and lead quality initiatives that meet national accreditation standards.
Health Disparities, Social Determinants of Health, and Health Equity
Despite national declines in overall breast cancer mortality over the past three decades, profound racial, socioeconomic, and geographic health disparities persist, representing a critical public health failure.
Epidemiologic Disparities in Breast Cancer
Black vs. White Mortality Disparity : Non-Hispanic Black women experience an approximate 40% higher breast cancer-related mortality rate compared to non-Hispanic White women, despite historically having a slightly lower or equivalent overall incidence of breast cancer. Black women are more frequently diagnosed at advanced regional or distant stages.
Triple-Negative Breast Cancer (TNBC) Prevalence : Premenopausal Black women exhibit a 2- to 3-fold higher incidence of triple-negative breast cancer (TNBC) and inflammatory breast cancer compared to White women. TNBC lacks ER, PR, and HER2 receptors, exhibits aggressive tumor biology with early visceral metastasis, and cannot be treated with targeted endocrine or HER2 receptor-directed agents.
Diagnostic and Treatment Delays : Disparities are heavily driven by structural barriers in healthcare delivery. Studies show that Black and Hispanic women wait longer, on average, between an abnormal screening mammogram and diagnostic resolution, and are more likely to experience delays in starting surgery, adjuvant chemotherapy, and radiation.
Disparities in Surgical and Genetic Care : Medically underserved and minority women experience significantly lower rates of immediate post-mastectomy breast reconstruction, lower rates of referral to hereditary cancer genetic counseling, and lower rates of enrollment in clinical trials.
Social Determinants of Health (SDOH) vs. Biology
While biological variations (such as higher TNBC prevalence) contribute to disparate outcomes, extensive epidemiological research confirms that Social Determinants of Health (SDOH) represent the primary drivers of disparate breast cancer mortality. SDOH encompass the conditions in which people are born, grow, live, work, and age, categorized into five broad domains:
Economic Stability : Poverty, underemployment, lack of paid medical leave, and food insecurity.
Education Access and Quality : Low health literacy, limited understanding of cancer genetics, and language barriers.
Healthcare Access and Quality : Lack of health insurance, Medicaid coverage gaps, geographic maldistribution of dedicated breast centers, and implicit provider bias.
Neighborhood and Built Environment : Living in rural or medically underserved urban areas without reliable public transportation, lacking access to healthy foods or safe recreational exercise spaces.
Social and Community Context : Historical medical mistrust stemming from systemic racism, lack of culturally congruent nursing care, and weak social support networks.
Breast care nurses champion health equity by implementing standardized SDOH screening at intake, utilizing professional medical interpreters (avoiding ad hoc family translators), offering evening and weekend clinical appointments, and establishing community-based mobile mammography screening programs.
- Financial Toxicity in Breast Oncology
- Definition and Clinical Sequelae
Financial toxicity refers to the devastating economic burden and subjective financial distress experienced by cancer patients as a result of the direct and indirect costs of medical care. Breast cancer is among the most financially draining malignancies due to the extensive duration of multimodal therapy, prolonged oral endocrine regimens (lasting 5 to 10 years), advanced diagnostic imaging (PET/CT, breast MRI), and expensive targeted biologics (antibody-drug conjugates, CDK4/6 inhibitors).
Direct Medical Costs : High insurance deductibles, co-insurance percentages, out-of-pocket prescription co-payments, and uncovered surgical supplies (such as post-mastectomy camisoles and custom lymphedema compression garments).
Indirect Non-Medical Costs : Loss of household income due to treatment-related disability, job termination, reduced work hours for patients and family caregivers, fuel, parking fees, and lodging expenses.
Financial toxicity is an established clinical toxicity with direct survival consequences. Research demonstrates that breast cancer patients experiencing severe financial toxicity are 2 to 3 times more likely to be non-adherent to life-saving adjuvant therapies —engaging in cost-coping behaviors such as skipping oral endocrine doses, splitting pills, delaying prescription refills, or canceling surveillance imaging. Severe financial distress is independently associated with bankruptcy, housing instability, food insecurity, major depression, diminished health-related quality of life, and an elevated risk of all-cause mortality.
Nursing Interventions to Mitigate Financial Toxicity
Routine Financial Distress Screening : Screen every newly diagnosed patient using validated clinical assessment tools, such as the COmprehensive Score for financial Toxicity (COST) measure.
Collaborative Care Coordination : Immediately connect distressed patients with specialized oncology financial counselors and oncology clinical social workers.
Navigating Assistance Programs : Assist patients in applying for pharmaceutical patient assistance programs (PAPs), foundation co-pay assistance grants (e.g., CancerCare, Patient Advocate Foundation, HealthWell Foundation), state Medicaid expansion programs, and local community charity funds.
Workplace Advocacy : Educate patients on their legal protections under the Family and Medical Leave Act (FMLA) and the Americans with Disabilities Act (ADA) regarding reasonable workplace accommodations during and following active treatment.
Multidisciplinary Tumor Boards (MTB) & Collaborative Practice
Modern breast cancer management is inherently multidisciplinary. The Multidisciplinary Tumor Board (MTB) —also referred to as a multidisciplinary cancer conference—represents the gold standard clinical forum for prospective, consensus-driven treatment planning.
Structure and Composition of the Breast MTB
A comprehensive breast tumor board brings together specialists from across the diagnostic and therapeutic spectrum:
Breast Surgical Oncologists : Presenting surgical considerations, technical feasibility of breast conservation vs. mastectomy, and axillary staging strategies.
Medical Oncologists : Evaluating indications for neoadjuvant vs. adjuvant chemotherapy, targeted biologics, immunotherapy, and endocrine regimens.
Radiation Oncologists : Designing radiation treatment volumes (partial breast, whole breast, regional nodal fields) and boost doses.
Dedicated Breast Radiologists : Reviewing mammographic, sonographic, and MRI findings, verifying lesion localization, and correlating imaging with clinical findings.
Breast Pathologists : Re-evaluating core needle biopsies and surgical resection specimens, assessing margin clearance, histologic subtype, grade, and biomarker expressions (ER/PR, HER2 IHC/FISH, Ki-67).
Reconstructive / Plastic Surgeons : Advising on oncoplastic techniques, tissue expander/implant placement, or autologous free-flap reconstruction.
Cancer Genetic Counselors : Identifying indications for multigene germline testing and integrating hereditary mutation results into surgical and systemic plans.
Oncology Nurse Navigators and Clinical Research Coordinators : Providing the holistic patient context and identifying clinical trial eligibility.
The Vital Role of the Breast Care Nurse in MTB
Prospective MTB review alters the primary diagnostic interpretation or therapeutic plan in 15% to 40% of reviewed breast cancer cases (such as identifying positive margins requiring re-excision, reclassifying equivocal HER2 tests, or identifying neoadjuvant chemotherapy candidacy). The breast care nurse plays a pivotal role in this forum by:
Presenting the patient's comprehensive functional status (ECOG performance status), comorbid conditions (cardiovascular disease, diabetes, renal failure), cognitive baseline, and home support systems.
Articulating the patient's personal preferences, religious values, cultural beliefs, and treatment goals (such as breast preservation desires or concerns regarding fertility preservation).
Ensuring that consensus clinical recommendations are translated back to the patient in an understandable, actionable manner, and resolving logistical barriers to plan execution.